Xcout Intel
Nephrogen
Nephrogen is a preclinical biotechnology company founded in 2022 and headquartered in New York, NY. The company is dedicated to developing curative genomic medicines for patients suffering from serious diseases.
Subscribe to see Nephrogen’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Nephrogen at a glance
Nephrogen is an application company headquartered in United States. It has raised at least $2M across the 2 funding rounds on record. Its most recent funding round, Pre-Seed, raised $2M in March 2026. Xcout tracks 3 named people at Nephrogen, including Chang Hong, JD (Chief Business Officer).
Nephrogen leadership
- Chang Hong, JDChief Business Officer
- Vivek Bhalla, MDChief Medical Advisor
- Demetri MaximChief Executive Officer
Nephrogen funding rounds
At least $2M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Pre-Seed | $2M | — | |
| Pre-Seed | $20,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Nephrogen competitors
A few of Nephrogen's closest competitors — see the full list of competitors and alternatives →
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
Unnatural Products Inc. is a biotechnology company developing orally-delivered macrocyclic peptides to address challenging therapeutic targets.
Gyroscope Therapeutics is a biotechnology company focused on developing gene therapies for retinal diseases. Headquartered in London, England, the company researches and designs advanced medical treatments for severe eye conditions.
Klotho Therapeutics, Inc. is a privately held biotechnology and life sciences company headquartered in San Diego, California. Founded in 2016, the venture-backed firm specializes in the synthetic replication of the Klotho protein.
Get Nephrogen's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Nephrogen in Xcout Intel
- 3 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access